DAP5 Antibody (3B5)

This product is produced by and distributed for Abnova, a company based in Taiwan.

Translation initiation is mediated by specific recognition of the cap structure by eukaryotic translation initiation factor 4F (eIF4F), which is a cap binding protein complex that consists of three subunits: eIF4A, eIF4E and eIF4G. The protein encoded by this gene shares similarity with the C-terminal region of eIF4G that contains the binding sites for eIF4A and eIF3; eIF4G, in addition, contains a binding site for eIF4E at the N-terminus. Unlike eIF4G, which supports cap-dependent and independent translation, this gene product functions as a general repressor of translation by forming translationally inactive complexes. In vitro and in vivo studies indicate that translation of this mRNA initiates exclusively at a non-AUG (GUG) codon. Alternatively spliced transcript variants encoding different isoforms of this gene have been described.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Showing Publications 1 - 2 of 2.

Publications using H00001982-M01	Applications	Species
Katsogiannou M, Andrieu C, Baylot V et al. The functional landscape of Hsp27 reveals new cellular processes such as DNA repair and alternative splicing and proposes novel anticancer targets. Mol Cell Proteomics 2014-10-02 [PMID: 25277244]
Kempf BJ, Barton DJ. Poliovirus 2APro Increased Viral mRNA and Polysome Stability Coordinate In Time with Cleavage of eIF4G. J Virol. 2008-04-09 [PMID: 18400852]

Array H00001982-M01

• DAP5 Antibodies
• DAP5 Lysate
• DAP5 Proteins